EpimAb_Logo Planegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered ...
Medigene AG and Epimab Biotherapeutics Inc. have entered a strategic codevelopment agreement to research and develop off-the-shelf T-cell receptor (TCR)-guided T-cell engagers (TCR-TCEs) for the ...
SHANGHAI, April 01, 2025 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to ...
SHANGHAI--(BUSINESS WIRE)--EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is excited to announce that the company will present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results